CO2021017958A2 - Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismas - Google Patents
Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismasInfo
- Publication number
- CO2021017958A2 CO2021017958A2 CONC2021/0017958A CO2021017958A CO2021017958A2 CO 2021017958 A2 CO2021017958 A2 CO 2021017958A2 CO 2021017958 A CO2021017958 A CO 2021017958A CO 2021017958 A2 CO2021017958 A2 CO 2021017958A2
- Authority
- CO
- Colombia
- Prior art keywords
- lysozyme
- infections
- formulation
- pharmaceutical formulation
- spectrum antibacterial
- Prior art date
Links
- 102000016943 Muramidase Human genes 0.000 title abstract 5
- 108010014251 Muramidase Proteins 0.000 title abstract 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title abstract 5
- 229960000274 lysozyme Drugs 0.000 title abstract 5
- 235000010335 lysozyme Nutrition 0.000 title abstract 5
- 239000004325 lysozyme Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000009291 secondary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853215P | 2019-05-28 | 2019-05-28 | |
| PCT/IB2020/055083 WO2020240472A1 (en) | 2019-05-28 | 2020-05-28 | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021017958A2 true CO2021017958A2 (es) | 2022-01-17 |
Family
ID=73551002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0017958A CO2021017958A2 (es) | 2019-05-28 | 2021-12-28 | Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismas |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200376094A1 (enExample) |
| EP (1) | EP3976093A4 (enExample) |
| JP (3) | JP7768769B2 (enExample) |
| CN (1) | CN114126643A (enExample) |
| AR (1) | AR119031A1 (enExample) |
| BR (1) | BR112021024001A2 (enExample) |
| CA (1) | CA3145530A1 (enExample) |
| CO (1) | CO2021017958A2 (enExample) |
| IL (1) | IL288531A (enExample) |
| MX (1) | MX2021014634A (enExample) |
| TW (1) | TW202110474A (enExample) |
| WO (1) | WO2020240472A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112805027B (zh) * | 2020-04-27 | 2023-10-10 | 广州新创忆药物临床研究有限公司 | 一种抗新冠病毒感染的药物与应用 |
| WO2021217702A1 (zh) * | 2020-04-27 | 2021-11-04 | 广州新创忆药物临床研究有限公司 | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 |
| WO2023133412A2 (en) * | 2022-01-05 | 2023-07-13 | Prophase Labs, Inc. | Compositions having synergistic anti-viral action and methods for treating coronavirus |
| CN114503981A (zh) * | 2022-01-07 | 2022-05-17 | 上海膜益信息科技有限公司 | 一种不分层防霉液及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| PT1755576E (pt) * | 2004-04-08 | 2011-10-19 | Dermcare Vet Pty Ltd | Composições antimicrobianas e métodos para a sua utilização |
| CN1583170A (zh) * | 2004-06-10 | 2005-02-23 | 安米 | 用于抗病毒抗耐药菌的人溶菌酶药物及其制法 |
| US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| US8097434B2 (en) * | 2007-10-19 | 2012-01-17 | Becton, Dickinson And Company | Methods for the detection of beta-lactamases |
| CN102223876A (zh) * | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CN111973484A (zh) * | 2013-03-12 | 2020-11-24 | 普莱玛疗法公司 | 包含螯合剂和碱的牙用组合物 |
| JP7055814B2 (ja) * | 2017-02-28 | 2022-04-18 | プリシジョンバイオティクス・グループ・リミテッド | 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム |
| US20200215169A1 (en) * | 2017-07-17 | 2020-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibacterial methods and related kits |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
-
2020
- 2020-05-28 AR ARP200101510A patent/AR119031A1/es unknown
- 2020-05-28 US US16/885,537 patent/US20200376094A1/en not_active Abandoned
- 2020-05-28 BR BR112021024001A patent/BR112021024001A2/pt unknown
- 2020-05-28 CN CN202080048142.9A patent/CN114126643A/zh active Pending
- 2020-05-28 WO PCT/IB2020/055083 patent/WO2020240472A1/en not_active Ceased
- 2020-05-28 JP JP2021571513A patent/JP7768769B2/ja active Active
- 2020-05-28 CA CA3145530A patent/CA3145530A1/en active Pending
- 2020-05-28 TW TW109117916A patent/TW202110474A/zh unknown
- 2020-05-28 MX MX2021014634A patent/MX2021014634A/es unknown
- 2020-05-28 EP EP20815355.1A patent/EP3976093A4/en not_active Withdrawn
-
2021
- 2021-11-29 IL IL288531A patent/IL288531A/en unknown
- 2021-12-28 CO CONC2021/0017958A patent/CO2021017958A2/es unknown
-
2022
- 2022-07-28 US US17/875,872 patent/US20220362354A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,472 patent/US20240066105A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215483A patent/JP2025038034A/ja active Pending
-
2025
- 2025-10-30 JP JP2025183379A patent/JP2026021451A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114126643A (zh) | 2022-03-01 |
| US20200376094A1 (en) | 2020-12-03 |
| TW202110474A (zh) | 2021-03-16 |
| BR112021024001A2 (pt) | 2022-01-25 |
| WO2020240472A1 (en) | 2020-12-03 |
| EP3976093A4 (en) | 2023-07-05 |
| AR119031A1 (es) | 2021-11-17 |
| CA3145530A1 (en) | 2020-12-03 |
| US20240066105A1 (en) | 2024-02-29 |
| EP3976093A1 (en) | 2022-04-06 |
| JP2026021451A (ja) | 2026-02-10 |
| JP2025038034A (ja) | 2025-03-18 |
| IL288531A (en) | 2022-01-01 |
| JP7768769B2 (ja) | 2025-11-12 |
| MX2021014634A (es) | 2022-07-04 |
| US20220362354A1 (en) | 2022-11-17 |
| JP2022534776A (ja) | 2022-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017958A2 (es) | Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismas | |
| MX2023006353A (es) | Sistema ultravioleta para el tratamiento intracorporal. | |
| BR112020015688A8 (pt) | Formulações tópicas que compreendem tofacitinibe | |
| ECSP18083443A (es) | Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
| JP2020527134A5 (enExample) | ||
| MX382255B (es) | Composiciones de suministro de farmaco implantables y metodos de uso de las mismas. | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| WO2020252061A8 (en) | Carabachol-bromonidine formulation to enhance anti-presbyopia effects | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
| EA201992759A1 (ru) | Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| CY1125075T1 (el) | Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| MX2023013226A (es) | Métodos para tratar, mejorar o prevenir infecciones mediante un tratamiento combinado de farmacos y vacunación. | |
| WO2020101790A3 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| EA202192234A1 (ru) | Комбинированная терапия для применения в лечении рака | |
| MX2023014234A (es) | Nuevo uso terapeutico de los inhibidores de la yodotironina desyodasa de tipo 2 (d2). | |
| MX2022001227A (es) | Metodos de tratamiento del cancer multifocal. | |
| MX2021016090A (es) | Lemborexant para el tratamiento de problemas del sueño. | |
| PH12022551384A1 (en) | Chronic wound healing composition and application thereof | |
| KR20200075335A (ko) | 피부병 치료제 | |
| MX2025005174A (es) | Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial |